Molecular Targeting Technologies, Inc. Licenses Cell Targeting Technology from the University of Notre Dame

March 1, 2010, West Chester, Pennsylvania, Molecular Targeting Technologies, Inc., (MTTI) announced that it has obtained an exclusive license from the University of Notre Dame for novel sensing technology developed by Professor Bradley Smith.

This unique technology can selectively target dead and dying mammalian cells as well as bacteria. When the targeting component is attached to a probe, it has been shown successfully to target mammary and prostate tumors and bacterial infection in mice.

According to Professor Bradley Smith, “This unique probe may be used to image cell death as a means to intervene early in diseases and rapidly determine the effectiveness of treatments. Imaging of cell death is broadly useful for treatment of numerous conditions, including cancer, cardiovascular diseases, neurology, renal diseases and even transplant rejection."

“We are excited to be working with MTTI on this technology,” said Richard Cox, the director of the Office of Technology Transfer at the University of Notre Dame. “MTTI has a track record of translating novel molecules from preclinical to the clinical setting and we look forward to seeing this technology applied to patients in the near future,” Cox said.

Chris Pak, President and CEO of MTTI said “This targeting probe can be used for *in vitro* applications as well as for *in vivo* molecular imaging. We believe that this technology has the potential to target myocardial ischemia, Alzheimer disease, cancer and bacterial infections. ”

"Initially, we will be launching a range of fluorescent versions of this robust phosphatidylserine (PS) targeting molecule for research applications. These products will be sold under the name PSVue™, and will be available in mid-March, 2010," said Dr. Brian Gray, Vice President of Research at MTTI.

University of Notre Dame

Founded in 1842, the University of Notre Dame is the nation's pre-eminent Catholic university and rated among the top 25 of all U.S. institutions of higher learning. Notre Dame offers its nearly 12,000 students a choice of over 60 undergraduate majors, 32 master's, and 23 doctoral degree programs. Rated as a Carnegie Doctoral/Research University-Extensive, Notre Dame boasts 4 colleges, 3 schools, 10 major research institutes, more than 40 centers and special programs, and the University's well-respected Hesburgh libraries system.

Molecular Targeting Technologies, Inc.

Molecular Targeting Technologies, Inc. (MTTI) is a privately held US based Biotechnology Company founded to develop novel medical imaging products for the diagnosis of cardiovascular disease and cancer. In addition, MTTI develops fluorescent probes and other research tools for use by the research community. Current research reagent product lines include CellVue®, NeuroVue®, SRfluor®, (novel proprietary fluorescent squaraine-rotaxane dyes with excellent fluorescence properties) and novel immobilized steroid beads.

Contact:
Chris Pak, e-mail: cpak@mtarget.com; Tel: (610) 738-7938
Richard Cox, e-mail: rcox@nd.edu; Tel: (574) 631-4551